A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States
In comparison with platinum-based chemotherapy, adjuvant alectinib offers substantial additional clinical and economic value to society.
Authors
- Jay M. Lee (ORCID: https://orcid.org/0000-0003-3715-6749)
- Amy L. Cummings (ORCID: https://orcid.org/0000-0003-0472-392X)
- Jesse Sussell (ORCID: https://orcid.org/0000-0002-9713-8983)
- Nick Jovanoski
- Sarika Ogale
- Fadoua El Moustaid (ORCID: https://orcid.org/0000-0002-9682-2417)
- Melina Arnold (ORCID: https://orcid.org/0000-0003-1700-6831)
- Celina Ngiam
- Katherine L. Rosettie (ORCID: https://orcid.org/0000-0002-3403-3295)
Institutions
- Roche (Switzerland) (CH)
- University of California, Los Angeles (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1097/coc.0000000000001248
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04